IRADIMED CORPORATION: research and development expense
Research and development expense for IRADIMED CORPORATION. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All IRADIMED CORPORATION financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 2,975,000 | USD | 2026-03-06 | 10-K · 0001104659-26-024691 |
| 2024-01-01 | 2024-12-31 | 2,832,000 | USD | 2026-03-06 | 10-K · 0001104659-26-024691 |
| 2023-01-01 | 2023-12-31 | 2,858,656 | USD | 2025-09-03 | 10-K/A · 0001558370-25-011853 |
| 2022-01-01 | 2022-12-31 | 2,278,081 | USD | 2024-03-01 | 10-K · 0001558370-24-002235 |
| 2021-01-01 | 2021-12-31 | 1,905,043 | USD | 2023-03-02 | 10-K · 0001104659-23-028003 |
| 2020-01-01 | 2020-12-31 | 1,902,530 | USD | 2022-03-04 | 10-K · 0001104659-22-030317 |
| 2019-01-01 | 2019-12-31 | 1,432,719 | USD | 2022-03-04 | 10-K · 0001104659-22-030317 |
| 2018-01-01 | 2018-12-31 | 1,517,112 | USD | 2021-03-05 | 10-K · 0001104659-21-032380 |
| 2017-01-01 | 2017-12-31 | 1,722,564 | USD | 2020-03-06 | 10-K · 0001104659-20-029891 |
| 2016-01-01 | 2016-12-31 | 1,347,507 | USD | 2019-03-07 | 10-K · 0001104659-19-013242 |
| 2015-01-01 | 2015-12-31 | 1,764,306 | USD | 2018-03-08 | 10-K · 0001104659-18-015709 |
| 2014-01-01 | 2014-12-31 | 1,068,674 | USD | 2017-03-10 | 10-K · 0001104659-17-015600 |
| 2013-01-01 | 2013-12-31 | 1,009,872 | USD | 2015-03-23 | 10-K · 0001104659-15-021769 |
Related financial histories
- IRADIMED CORPORATION: total assets
- IRADIMED CORPORATION: total liabilities
- IRADIMED CORPORATION: stockholders equity
- IRADIMED CORPORATION: cash and cash equivalents
- IRADIMED CORPORATION: net income or loss
- IRADIMED CORPORATION: operating cash flow
- IRADIMED CORPORATION: capital expenditure payments
- IRADIMED CORPORATION: revenue
- IRADIMED CORPORATION: contract revenue excluding tax
- IRADIMED CORPORATION: financing cash flow
- IRADIMED CORPORATION: investing cash flow
- IRADIMED CORPORATION: retained earnings or deficit
- IRADIMED CORPORATION: basic weighted-average shares
- IRADIMED CORPORATION: diluted weighted-average shares
- IRADIMED CORPORATION: basic earnings per share
- IRADIMED CORPORATION: diluted earnings per share
- IRADIMED CORPORATION: income tax expense or benefit
- IRADIMED CORPORATION: net property, plant and equipment
- IRADIMED CORPORATION: share-based compensation expense
- IRADIMED CORPORATION: operating income or loss
- IRADIMED CORPORATION: current assets
- IRADIMED CORPORATION: current liabilities
- IRADIMED CORPORATION: current accounts payable
- IRADIMED CORPORATION: net finite-lived intangible assets
- IRADIMED CORPORATION: net current accounts receivable
- IRADIMED CORPORATION: operating expenses
- IRADIMED CORPORATION: net inventory
- IRADIMED CORPORATION: gross profit
- IRADIMED CORPORATION: cost of revenue
Inspect the source
- Entity
- IRADIMED CORPORATION / CIK 0001325618
- Captured
- 2026-09-20T07:52:33.517Z
- SEC response SHA-256
1217db54631fdc625eb836a9c89fbf1ed157044af9ce59b6e200421c6d8ca994
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001325618.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))